Skip to content
evident
Original paper
2005NEJMHematology/Oncology

HERA

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

RCTBreast cancer

On this page

Overview

Adjuvant trastuzumab improved disease-free survival in HER2-positive early breast cancer.

Clinical takeaway

HERA helped establish HER2-targeted therapy as a standard adjuvant treatment, transforming HER2-positive breast cancer from a poor-prognosis subtype into a targetable disease.

Key result

One year of trastuzumab reduced disease-free survival events versus observation after chemotherapy (127 vs 220 events; HR 0.54; 95% CI 0.43-0.67).

Practice impact

HER2 testing and adjuvant trastuzumab became routine in eligible early breast cancer.

Evidence

Study design

Randomized open-label trial after completion of surgery and chemotherapy.

Enrollment

5,081

Follow-up

Median 1 year at interim efficacy report; later long-term follow-up confirmed durable benefit.

Geography

Multinational

Clinical question

Does adjuvant trastuzumab improve disease-free survival after chemotherapy in HER2-positive early breast cancer?

Population

  • Women with HER2-positive early breast cancer who had completed locoregional therapy and chemotherapy.

Intervention

Trastuzumab every 3 weeks for 1 year after chemotherapy.

Comparator

Observation after chemotherapy.

Primary outcome

Disease-free survival.

Adjuvant trastuzumab substantially reduced recurrence risk after chemotherapy in HER2-positive early breast cancer.

Hazard ratio / 0.54 / 95% CI 0.43-0.67 / p<0.0001

Key results

  • One year of trastuzumab significantly improved disease-free survival: 127 vs 220 events; HR 0.54 (95% CI 0.43-0.67; P<0.0001); absolute DFS benefit 8.4 percentage points at 2 years.
  • Overall survival was not significantly different at this first interim analysis (29 vs 37 deaths).
  • Distant recurrence was reduced.
  • Cardiac dysfunction was more common with trastuzumab and required monitoring.

Harms

  • Symptomatic congestive heart failure and reduced left ventricular ejection fraction were more common with trastuzumab.
  • Infusion reactions and cardiotoxicity monitoring are practical concerns.

Clinical Use

Practice impact

  • Made HER2 testing and HER2-targeted adjuvant therapy central to early breast cancer management.

Applicability

  • Patients with HER2-positive early breast cancer eligible for adjuvant systemic therapy and cardiac monitoring.

Limitations

  • Open-label design.
  • Contemporary regimens may use different chemotherapy backbones and additional HER2-targeted agents.

Common misinterpretations

  • Do not ignore cardiac risk; trastuzumab benefit comes with a need for baseline and interval cardiac assessment.

Related evidence

NSABP B-06 - Same Disease

Citation

Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659-1672. doi:10.1056/NEJMoa052306

One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer.